Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Neumología y cirugía de tórax
versión impresa ISSN 0028-3746
Resumen
BARRESE PEREZ, Yinet et al. Safety’s evaluation the post-commercial use of Cuban surfactant, SURFACEN®, in the treatment of acute respiratory distress syndrome in adults. Neumol. cir. torax [online]. 2019, vol.78, n.3, pp.296-303. Epub 12-Feb-2021. ISSN 0028-3746.
Objective:
To corroborate the safety of the combined treatment of Surfacen® with standard oxygenation and mechanical ventilation therapy in the treatment of acute respiratory distress syndrome in adults.
Material and methods:
Adult patients with acute respiratory distress syndrome (141) included in a phase IV clinical trial, multicenter, uncontrolled, not randomized, open, in which the endotracheal instillation of 100 mg SURFACEN® was indicated every 8 hours for three days in combination with conventional oxygenation and mechanical ventilation therapy. Adverse events were identified and quantified, which were classified according to severity, seriousness and causality with respect to the instillation of the surfactant and mortality was analyzed at day 28 after the patients had been included in the study.
Results:
Non-serious adverse events (57.60%) predominated, non-severe intensity (26.72% mild and 42.89% moderate), unrelated to surfactant instillation (66.67%), predominated. reversible (87.75%) and that did not cause changes in the treatment (95.02%). Fever and hypotension were the most frequently reported adverse events.
Conclusion:
The treatment of acute respiratory distress syndrome with SURFACEN® in combination with oxygenation and mechanical ventilation is safe.
Palabras llave : Adults; acute respiratory distress syndrome; security; surfactant.